Ikena
Mar 30, 2021
Bright Peak, Ajinomoto to Create Novel Immunocytokines; FDA’s Rejection to Lilly/Pfizer’s Tanezumab for Osteoarthritis Pain; Ikena Oncology Unveils IPO Pricing
Bright Peak Therapeutics, Ajinomoto Collaborates to Create Novel Immunocytokines Bright Peak Therapeutics has announced a research and licensing collaboration with Ajinomoto to incorporate AJICAP, Ajinomoto Co.’s proprietary site-specific bioconjugation technology, for the development of Bright Peak Immuno...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
